Internal Medicine, Hematology & Oncology · Belleville, NJ
NPI
1447236617
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
6
Medicare group memberships
Hospitals
4
Hospital affiliations
1 Clara Maass Dr Ste 200
Belleville, NJ, 07109
Phone (973) 751-8880
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.1M
101,521 services
Medicare patients, 2024
718
Average age 76
Drug cost, 2024
$3.2M
1,250 prescriptions
Company payments, 2025
$6,845
From 43 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Said Saleh was code J1439 (injection, ferric carboxymaltose, 1 mg), 24,000 times for 15 patients. In total Said Saleh billed 101,521 services in 106 codes, and Medicare paid $1.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-02-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 24,000 | 15 | $0.84 | $20K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 19,890 | 15 | $0.27 | $5,332 |
| 99232 Hospital E&M - Subsequent | Facility | 2,915 | 429 | $66.39 | $194K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,132 | 15 | $0.09 | $102 |
| 36415 Venipuncture Blood Collection | Office | 762 | 201 | $8.64 | $6,583 |
| 85025 Blood Count | Office | 762 | 204 | $7.53 | $5,738 |
| 99291 Critical Care E&M | Facility | 477 | 137 | $178.76 | $85K |
| 99214 Office E&M - Established | Office | 393 | 166 | $105.95 | $42K |
| 99222 Hospital E&M - Initial | Facility | 379 | 315 | $109.94 | $42K |
| 99213 Office E&M - Established | Office | 189 | 121 | $66.94 | $13K |
| 96367 Intravenous Infusion, Hydration | Office | 170 | 34 | $24.57 | $4,177 |
| 96365 Intravenous Infusion, Hydration | Office | 166 | 45 | $55.28 | $9,176 |
| 96375 Injection Administration | Office | 146 | 17 | $13.83 | $2,019 |
| 96413 Chemotherapy Administration | Office | 120 | 15 | $111.27 | $13K |
| 96372 Injection Administration | Office | 114 | 26 | $12.51 | $1,426 |
By year: 2022 $1.4M for 112,379 services; 2023 $1.4M for 118,814 services; 2024 $1.1M for 101,521 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 762 | 201 | $8.64 | $6,583 |
| 85025 Blood Count | 762 | 204 | $7.53 | $5,738 |
Medicare prescription drug claims, 2024
In 2024, the drug Said Saleh prescribed most often to Medicare patients was Keytruda (Pembrolizumab), with 96 prescriptions and refills. In total Said Saleh wrote 1,250 Medicare prescriptions that cost $3.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Keytruda Pembrolizumab | 96 | 96 | Under 11 | $1.1M |
| Eliquis Apixaban | 60 | 62 | 19 | $37K |
| Anastrozole Generic | 57 | 95 | 14 | $535 |
| Alprazolam Generic | 55 | 57 | 17 | $564 |
| Opdivo Nivolumab | 33 | 33 | Under 11 | $516K |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 31 | 31 | 15 | $557 |
| Prednisone Generic | 31 | 31 | Under 11 | $207 |
| Lupron Depot Leuprolide Acetate | 30 | 30 | Under 11 | $31K |
| Zoledronic Acid Generic | 28 | 36 | Under 11 | $6,371 |
| Dexamethasone Sodium Phosphate Dexamethasone Sodium Phosp/Pf | 24 | 24 | Under 11 | $183 |
| Abiraterone Acetate Generic | 23 | 23 | Under 11 | $23K |
| Xarelto Rivaroxaban | 22 | 26 | Under 11 | $15K |
| Palonosetron Hcl Generic | 21 | 21 | Under 11 | $551 |
| Hydroxyurea Generic | 19 | 31 | Under 11 | $406 |
| Fosaprepitant Dimeglumine Generic | 18 | 18 | Under 11 | $651 |
Brand drugs: 422 claims; generic drugs: 828 claims; opioid claims: 65.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Said Saleh $6,845 ($6,845 in general payments such as food, travel and fees) from 43 companies. The largest payer was Avyxa Pharma, LLC with $3,093.
| Company | Payments | Amount |
|---|---|---|
| Avyxa Pharma, LLC | 6 | $3,093 |
| E.R. Squibb & Sons, L.L.C. BMY | 19 | $413 |
| AstraZeneca Pharmaceuticals LP AZN | 17 | $396 |
| GlaxoSmithKline, LLC. GSK | 11 | $395 |
| Janssen Biotech, Inc. JNJ | 10 | $340 |
| Daiichi Sankyo Inc. 4568.T | 12 | $211 |
| Incyte Corporation INCY | 7 | $201 |
| Stemline Therapeutics Inc. | 4 | $177 |
| Abbvie Inc. ABBV | 4 | $176 |
| Genzyme Corporation SNY | 6 | $132 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.